PT  - JOURNAL ARTICLE
AU  - Magni, Peter Dutey
AU  - Williams, Haydn
AU  - Jhass, Arnoupe
AU  - Rait, Greta
AU  - Lorencatto, Fabiana
AU  - Hemingway, Harry
AU  - Hayward, Andrew
AU  - Shallcross, Laura
TI  - Covid-19 infection and attributable mortality in UK Long Term Care Facilities: Cohort study using active surveillance and electronic records (March-June 2020)
AID  - 10.1101/2020.07.14.20152629
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.14.20152629
4099  - http://medrxiv.org/content/early/2020/07/15/2020.07.14.20152629.short
4100  - http://medrxiv.org/content/early/2020/07/15/2020.07.14.20152629.full
AB  - Background Rates of Covid-19 infection have declined in many countries, but outbreaks persist in residents of long-term care facilities (LTCFs) who are at high risk of severe outcomes. Epidemiological data from LTCFs are scarce. We used population-level active surveillance to estimate incidence of, and risk factors for Covid-19, and attributable mortality in elderly residents of LTCFs.Methods Cohort study using individual-level electronic health records from 8,713 residents and daily counts of infection for 9,339 residents and 11,604 staff across 179 UK LTCFs. We modelled risk factors for infection and mortality using Cox proportional hazards and estimated attributable fractions.Findings 2,075/9,339 residents developed Covid-19 symptoms (22·2% [95% confidence interval: 21·4%; 23·1%]), while 951 residents (10·2% [9·6%; 10·8%]) and 585 staff (5·0% [4·7%; 5·5%]) had laboratory confirmed infections. Confirmed infection incidence in residents and staff respectively was 152·6 [143·1; 162·6] and 62·3 [57·3; 67·5] per 100,000 person-days. 121/179 (67·6%) LTCFs had at least one Covid-19 infection or death. Lower staffing ratios and higher occupancy rates were independent risk factors for infection.1,694 all-cause deaths occurred in 8,713 (19·4% [18·6%; 20·3%]) residents. 217 deaths occurred in 607 residents with confirmed infection (case-fatality rate: 35·7% [31·9%; 39·7%]). 567/1694 (33·5%) of all-cause deaths were attributable to Covid-19, 28·0% of which occurred in residents with laboratory-confirmed infection. The remainder of excess deaths occurred in asymptomatic or symptomatic residents in the context of limited testing for infection, suggesting substantial under-ascertainment.Interpretation 1 in 5 residents had symptoms of infection during the pandemic, but many cases were not tested. Higher occupancy and lower staffing levels increase infection risk. Disease control measures should integrate active surveillance and testing with fundamental changes in staffing and care home occupancy to protect staff and residents from infection.Funding Economic and Social Research Council [ES/V003887/1].Competing Interest StatementFL, GR, LS are supported by research funding from the ESRC. LS is a member of the Care Home working group, a subgroup of the Scientific Advisory Group for Emergencies. AH is a member of the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG). All other authors declare no competing interests.Funding StatementThis work was supported by the Economic and Social Research Council [ES/V003887/1]. This work was also supported by a National Institute for Health Research (NIHR) Clinician Scientist award (CS-2016-007 to L.S.); In-Practice fellowship (NIHR300293 to A.J.); the NIHR School of Primary Care Research (G.R). AH and HH are NIHR Senior Investigators. AH and HH are supported by Health Data Research UK (grant No. LOND1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, Wellcome Trust. HH is funded by the NIHR University College London Hospitals Biomedical Research Centre, The BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No. 116074.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University College London Research Ethics Committee (project reference 13355/002).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll computer syntax used in the analysis is available through an online repository. The data that support the findings of this study are available from the Four Seasons Healthcare Group but restrictions apply to the availability of these data, which were used under a data sharing agreement for the current study and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Four Seasons Healthcare Group. https://github.com/peterdutey/ch-covid19